Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 24, 2021

Primary Completion Date

December 16, 2022

Study Completion Date

March 30, 2023

Conditions
Achondroplasia
Interventions
BIOLOGICAL

Recifercept

Recifercept

Trial Locations (14)

2100

Bispebjerg Hospital, Copenhagen

2400

Bispebjerg Hospital, Copenhagen

2650

Antwerp University Hospital, Edegem

3000

UZ Leuven - Center of Human Genetics, Leuven

3052

Murdoch Children's Research Institute, Parkville

19803

Nemours Children's Hospital, Delaware, Wilmington

77030

Texas Childrens Hospital/Baylor College of Medicine, Houston

90502

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

90806

Long Beach Memorial Medical Center, Long Beach

MemorialCare Sleep Disorders Center at Long Beach Memorial Medical Center, Long Beach

92604

Ocean Sleep Medicine, Irvine

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Roma

3000-602

Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico, Coimbra

01008

Hospital Vithas San Jose, Vitoria-Gasteiz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05116046 - Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia | Biotech Hunter | Biotech Hunter